295 related articles for article (PubMed ID: 29262888)
41. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
[TBL] [Abstract][Full Text] [Related]
42. U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity.
Badar T; Vanegas YAM; Nanaa A; Foran JM; Al-Kali A; Mangaonkar A; Murthy H; Alkhateeb HB; Viswanatha D; He R; Shah M; Yi CA; Litzow MR; Gangat N; Tefferi A; Patnaik MM
Blood Cancer J; 2023 Sep; 13(1):149. PubMed ID: 37735430
[TBL] [Abstract][Full Text] [Related]
43. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
[TBL] [Abstract][Full Text] [Related]
44. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
45. Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53.
Siddon AJ; Weinberg OK
Clin Lab Med; 2023 Dec; 43(4):607-614. PubMed ID: 37865506
[TBL] [Abstract][Full Text] [Related]
46. [Flt-3/ITD mutation in pediatric leukemia and its clinical significance].
Wang J; Wang T; Li S; Lin L; Gang Y
Ai Zheng; 2007 Jan; 26(1):58-63. PubMed ID: 17222369
[TBL] [Abstract][Full Text] [Related]
47. Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations.
West AH; Godley LA; Churpek JE
Ann N Y Acad Sci; 2014 Mar; 1310(1):111-8. PubMed ID: 24467820
[TBL] [Abstract][Full Text] [Related]
48. [Genomic aberrations in myelodysplastic syndromes and related disorders].
Makishima H
Rinsho Ketsueki; 2019; 60(6):600-609. PubMed ID: 31281151
[TBL] [Abstract][Full Text] [Related]
49. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
[TBL] [Abstract][Full Text] [Related]
50. Morphologic, immunophenotypic, and molecular genetic comparison study in patients with clonal cytopenia of undetermined significance, myelodysplastic syndrome, and acute myeloid leukemia with myelodysplasia-related changes: A single institution experience.
Gao L; Hyter S; Zhang D; Kelting S; Woodroof J; Abdallah AO; Yacoub A; McGuirk J; Abdelhakim H; Godwin AK; Cui W
Int J Lab Hematol; 2022 Aug; 44(4):738-749. PubMed ID: 35352484
[TBL] [Abstract][Full Text] [Related]
51. [Comparison of chromosome karyotype between myelodysplastic syndrome and acute leukemia patients confirmed at the same period].
Jiang M; Wen BZ; Li L; Chen S; Cheng H; Hao JP; Chen R; Wang L; Zhao F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):387-92. PubMed ID: 24763010
[TBL] [Abstract][Full Text] [Related]
52. A genetic development route analysis on MDS subset carrying initial epigenetic gene mutations.
Li X; Xu F; Wu LY; Zhao YS; Guo J; He Q; Zhang Z; Chang CK; Wu D
Sci Rep; 2020 Jan; 10(1):826. PubMed ID: 31964915
[TBL] [Abstract][Full Text] [Related]
53. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.
Weinberg OK; Siddon A; Madanat YF; Gagan J; Arber DA; Dal Cin P; Narayanan D; Ouseph MM; Kurzer JH; Hasserjian RP
Blood Adv; 2022 May; 6(9):2847-2853. PubMed ID: 35073573
[TBL] [Abstract][Full Text] [Related]
54. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
[TBL] [Abstract][Full Text] [Related]
55. [Analysis of RUNX1 Gene Mutation in Patients with Myelodysplastic Syndrome].
Cai XH; Chen MY; Chao HY; Jiang NK; Lu XZ; Han WM; Qin W; Jia ZX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):202-208. PubMed ID: 32027277
[TBL] [Abstract][Full Text] [Related]
56. Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission.
Sun Y; Shen H; Xu T; Yang Z; Qiu H; Sun A; Chen S; Wu D; Xu Y
Leuk Res; 2016 Oct; 49():102-7. PubMed ID: 27626217
[TBL] [Abstract][Full Text] [Related]
57. U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
Qian J; Yao DM; Lin J; Qian W; Wang CZ; Chai HY; Yang J; Li Y; Deng ZQ; Ma JC; Chen XX
PLoS One; 2012; 7(9):e45760. PubMed ID: 23029227
[TBL] [Abstract][Full Text] [Related]
58. Comprehensive analysis of genetic factors predicting overall survival in Myelodysplastic syndromes.
Maurya N; Mohanty P; Dhangar S; Panchal P; Jijina F; Mathan SLP; Shanmukhaiah C; Madkaikar M; Vundinti BR
Sci Rep; 2022 Apr; 12(1):5925. PubMed ID: 35396491
[TBL] [Abstract][Full Text] [Related]
59. Clinical utility and real-world application of molecular genetic sequencing in the management of patients with acute myeloid leukemia and myelodysplastic syndromes.
Banaszak LG; Reinig E; Lasarev MR; Mattison RJ
Leuk Lymphoma; 2022 Mar; 63(3):684-693. PubMed ID: 34865601
[TBL] [Abstract][Full Text] [Related]
60. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
